Real-World Data Compare Tirzepatide and SGLT2 Inhibitors in MASLD Outcomes

Mohammad Alabbas, MD, presents real-world data comparing the effects of tirzepatide versus SGLT2 inhibitors on liver and cardiovascular outcomes in patients with MASLD. This analysis spans multiple stages of the disease, providing insights into treatment impacts across the MASLD spectrum.

Originally published by gnews